The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 04, 2018

Filed:

Feb. 15, 2018
Applicant:

King Saud University, Riyadh, SA;

Inventors:

Abd El-Galil E. Amr, Riyadh, SA;

Mohamed A. Al-Omar, Riyadh, SA;

Abdulrahman A. Almehizia, Riyadh, SA;

Assignee:

KING SAUD UNIVERSITY, Riyadh, SA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/216 (2006.01); A61K 31/265 (2006.01); A61K 31/365 (2006.01); A61P 35/00 (2006.01); A61K 31/167 (2006.01);
U.S. Cl.
CPC ...
A61K 31/265 (2013.01); A61K 31/167 (2013.01); A61K 31/216 (2013.01); A61K 31/365 (2013.01); A61P 35/00 (2018.01);
Abstract

The abietic acid derivatives as anti-tumor agents are derivatives of abietic acid in which the hydroxyl entity (—OH) of the carboxyl entity is replaced by an electronegative substituent, which may be C6H5-O—, C6H5-S—, or C6H5-NH—, and a hydrogen atom on one of the rings is replaced by a hydroxyl (—OH) substituents, the derivatives having the formula: wherein X is O, S, or NH. The derivatives are formed by formation of an intermediate lactone from abietic acid, followed by reaction of the lactone with phenol, thiophenol, or aniline. All of the derivatives exhibited potent 5α-reductase inhibitor activity, both in vitro and in vivo, and anti-tumor activity with regard to two prostate cancer cell lines—LNCaP and PC-3. The intermediate lactones are also derivatives of abietic acid that exhibit anti-tumor activity.


Find Patent Forward Citations

Loading…